CABGNCT06766123
Outcomes of Coronary Artery Bypass Grafting in Israeli Jews and Arabs
An observational study of CABG and Ethnic Group, run by Technion, Israel Institute of Technology.
Trial summary
Retrospective study of adult patients with multivessel disease undergoing isolated CABG in three centers between January 1st, 2009, and December 31st, 2023. The primary outcome was a composite of major adverse cardiac and cerebrovascular events (MACCE). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- CABG, Ethnic Group
- What is being tested?
- CABG
- Type of treatment
- Surgery or procedure
- How many people
- 7,067 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2009to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients undergoing isolated CABG at Carmel medical center, Beilinson medical center and Soroka medical center at Israel
Who may be able to join
- isolated CABG
Who cannot join
- members of different HMO
About this study
Retrospective study of adult patients with multivessel disease undergoing isolated CABG in three centers between January 1st, 2009, and December 31st, 2023. The primary outcome was a composite of major adverse cardiac and cerebrovascular events (MACCE). Patients were grouped according to their ethnic origin, Arabs and Jews.
- Conditions
- CABG, Ethnic Group
- Being tested
- CABG
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CABGProcedure or surgery
All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities
| Study group | Role | What they receive |
|---|---|---|
| Arab ethnicity | All Arab patients undergoing isolated CABG Receives: Procedure: CABG | |
| Jew ethnicity | All Jew patients undergoing isolated CABG Receives: Procedure: CABG |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACCE
Measured: through study completion, a median of 78 months
Secondary outcomes (5)
Mortality
Measured: through study completion, a median of 78 months
MI
Measured: through study completion, a median of 78 months
CVA
Measured: through study completion, a median of 78 months
repeat revascularization
Measured: through study completion, a median of 78 months
utilization of multi-arterial grafting
Measured: through study completion, a median of 78 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2025
- Study start1 Jan 2009
- Primary completion31 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CABGStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 7,067 participants (actual)
Sponsor and investigators
- Lead sponsor
- Technion, Israel Institute of Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dror B. Leviner, Technion, Israel Institute of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06766123
- Sponsor's protocol ID
- CMC 21-175
- Status last verified
- Jan 2025
- First submitted
- 27 Dec 2024
- Last updated
- 9 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes of Coronary Artery Bypass Grafting in Israeli Jews and Arabs
- ClinicalTrials.gov ID
- NCT06766123
- Acronym / sponsor ID
- CMC 21-175
- Conditions
- CABG, Ethnic Group
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 7,067 participants (actual)
- Lead sponsor
- Technion, Israel Institute of TechnologyUniversity, hospital or other
- Study start
- 1 Jan 2009 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 9 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Retrospective study of adult patients with multivessel disease undergoing isolated CABG in three centers between January 1st, 2009, and December 31st, 2023. The primary outcome was a composite of major adverse cardiac and cerebrovascular events (MACCE). Patients were grouped according to their ethnic origin, Arabs and Jews.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arab ethnicity | – | Procedure: CABGAll Arab patients undergoing isolated CABG |
| Jew ethnicity | – | Procedure: CABGAll Jew patients undergoing isolated CABG |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients undergoing isolated CABG at Carmel medical center, Beilinson medical center and Soroka medical center at Israel
Key inclusion criteria (1 listed)
- isolated CABG
Key exclusion criteria (1 listed)
- members of different HMO
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CABGAll patients underwent isolated CABG and retrospectively followed to asses ethnic disparities | Procedure or surgery | Arab ethnicity, Jew ethnicity |
Primary outcome
MACCE
Time frame: through study completion, a median of 78 months
5 secondary outcomes
Mortality
Time frame: through study completion, a median of 78 months
MI
Time frame: through study completion, a median of 78 months
CVA
Time frame: through study completion, a median of 78 months
repeat revascularization
Time frame: through study completion, a median of 78 months
utilization of multi-arterial grafting
Time frame: through study completion, a median of 78 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2025.
Related trials for CABG
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Anaesthetic Management in Patients Undergoing Coronary Artery Bypass Grafting
Preoperative Fasting, Pulmonary Aspiration During Anesthetic Induction
Active, not recruiting
Investigation of the Effects of Respiratory Muscle Training Combined With Otago Exercises in Elderly Patients Undergoing Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass Graft (CABG)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of CABG and Ethnic Group, run by Technion, Israel Institute of Technology.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACCE (time frame: through study completion, a median of 78 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2025.